Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi Aventis Deutschland GmbH
Update Il y a 4 ans
Health Assessment, Patient treatment satisfaction and Quality-of-Life in insulin-naive type 2 diabetes Patients uncontrolled on OHA treatment initiating basal insulin therapy with either insulin glargine or NPH insulin added to therapies with oral hypoglycemic agents. A multicenter, prospective, crossover, open randomized clinical phase-IV trial
Investigate the impact of insulin glargine vs. NPH basal insulin on a composite diabetes related quality of life score (DRQoL), consisting of a standardized and unweighted Insulin Treatment Experience...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis recherche & de`veloppement
Update Il y a 4 ans
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung cancer Studio di fase 2 randomizzato con gemcitabina/cisplatino somministrati da soli o in combinazione a SAR240550 (BSI-201), un PARP-1inibitore, in pazienti affetti da carcinoma polmonare non a piccole cellule in stadio IV
Primary objective is to assess the objective response rate (ORR) of SAR240550 administered as a 60-min intravenous infusion twice weekly, when combined to gemcitabine/cisplatin chemotherapy regimen (G...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TCD10620 : Essai de phase 1 évaluant la tolérance et la pharmacocinétique d’un traitement associant de l’AVE8062, du cisplatine et du docétaxel, chez des patients ayant une tumeur solide avancée. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la plus adaptée de l’AVE8062 à administrer en association avec une chimiothérapie, chez des patients ayant une tumeur solide avancée. Les patients re...
Country
France
organs
Tumeurs solides
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi S.p.A
Update Il y a 4 ans
studio di fase IV, della durata di 24 settimane che ha lo scopo di dimostrare la non inferiorità di un algoritmo con gestione del paziente rispetto a quello con gestione del medico per la titolazione di insulina glargine 300U/ml (HOE901-U300)
The primary objective of this study is to demonstrate the non-inferiority, in terms of glycemic control, of a patient-managed (nurse assisted) versus a physician-managed algorithm for titrating Insuli...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
COMPARISON OF TWO THERAPEUTIC STRATEGIES FOR TREATING TYPE 2 DIABETIC PATIENTS POORLY CONTROLLED WITH BASAL INSULIN ASSOCIATED WITH ORAL ANTIDIABETIC DRUGS: 6-MONTH PROOF OF CONCEPT STUDY
The primary objective of the study is to evaluate the efficacy (measured by the percentage of patients achieving an Hemoglobin A1c (HbA1c) level at the end of treatment period < 7%) of a single inject...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Groupe
Update Il y a 4 ans
Estudio aleatorizado, doble ciego, de dos brazos, controlado con placebo y de 12 meses de duración de los efectos de rimonabant 20 mg una vez al día sobre la cantidad y actividad de la grasa visceral en pacientes con obesidad abdominal y síndrome metabólico. A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20 mg once daily on the amount and the activity of visceral fat in abdominally obese patients with metabolic syndrome
Evaluar el efecto del rimonabant sobre el area grasa visceral durante un periodo de 12 meses al ser administrado con una dieta hipocalórica moderada a pacientes con obesidad abdominal y síndrome meta...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Produtos Farmaceuticos, S.A
Update Il y a 4 ans
Alfuzosin in Uretheric Stones
To assess the effect of Alfuzosin compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to E.S.W.L., namely in the percentage of patients without imagiologic ev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TROPIC : Essai de phase 3, randomisé comparant l’efficacité d’un traitement associant la prednisone au XRP6258, ou à la mitoxantrone, chez les patients ayant un cancer de la prostate métastatique, précédemment traité par un schéma à base de doxétaxel et réfractaire à l’hormonothérapie. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer la tolérance et l’efficacité d’un traitement associant le XRP6258 et la prednisone à un traitement associant la mitoxantrone et la prednisone dans le traitement...
Country
France
organs
Prostate
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients
The primary objective of this study is to assess the clinical efficacy response rate using ACR20 criteria as primary endpoint at 3-month in each initial dosing regimen group of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety Study of a Hexavalent DTaP-IPV-HB-Hib Combined Vaccine in a 3-dose Primary Series in Healthy Infants in Europe Estudio de inmunogenicidad y de seguridad de una vacuna combinada hexavalente DTaP-IPV-HB-Hib en una serie primaria de 3 dosis en lactantes sanos en Europa
Groups 1 and 2 only To demonstrate the non-inferiority of the DTaP-IPV-HB-Hib vaccine to the control Infanrix hexa vaccine, both co-administered with Prevenar 13, in terms of seroprotection or vaccine...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next